
Amy E. Juedes
Examiner (ID: 7188)
| Most Active Art Unit | 1644 |
| Art Unit(s) | 1644 |
| Total Applications | 1249 |
| Issued Applications | 438 |
| Pending Applications | 166 |
| Abandoned Applications | 692 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20134805
[patent_doc_number] => 20250241849
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-31
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 19/083100
[patent_app_country] => US
[patent_app_date] => 2025-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20343
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 175
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19083100
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/083100 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL DYSFUNCTION | Mar 17, 2025 | Pending |
Array
(
[id] => 20134805
[patent_doc_number] => 20250241849
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-31
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 19/083100
[patent_app_country] => US
[patent_app_date] => 2025-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20343
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 175
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19083100
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/083100 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL DYSFUNCTION | Mar 17, 2025 | Pending |
Array
(
[id] => 19615001
[patent_doc_number] => 20240400681
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => METHOD FOR PRODUCING AN ANTI-LAG-3 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 18/767925
[patent_app_country] => US
[patent_app_date] => 2024-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18767925
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/767925 | METHOD FOR PRODUCING AN ANTI-LAG-3 ANTIBODY | Jul 8, 2024 | Pending |
Array
(
[id] => 19707883
[patent_doc_number] => 20250018025
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR)
[patent_app_type] => utility
[patent_app_number] => 18/670211
[patent_app_country] => US
[patent_app_date] => 2024-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18670211
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/670211 | AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR) | May 20, 2024 | Pending |
Array
(
[id] => 19707883
[patent_doc_number] => 20250018025
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR)
[patent_app_type] => utility
[patent_app_number] => 18/670211
[patent_app_country] => US
[patent_app_date] => 2024-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18670211
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/670211 | AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR) | May 20, 2024 | Pending |
Array
(
[id] => 19450233
[patent_doc_number] => 20240310363
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => METHODS FOR USING ENRICHED EXOSOMES AS A PLATFORM FOR MONITORING ORGAN STATUS
[patent_app_type] => utility
[patent_app_number] => 18/625699
[patent_app_country] => US
[patent_app_date] => 2024-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34550
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18625699
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/625699 | METHODS FOR USING ENRICHED EXOSOMES AS A PLATFORM FOR MONITORING ORGAN STATUS | Apr 2, 2024 | Pending |
Array
(
[id] => 19450233
[patent_doc_number] => 20240310363
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => METHODS FOR USING ENRICHED EXOSOMES AS A PLATFORM FOR MONITORING ORGAN STATUS
[patent_app_type] => utility
[patent_app_number] => 18/625699
[patent_app_country] => US
[patent_app_date] => 2024-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34550
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18625699
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/625699 | METHODS FOR USING ENRICHED EXOSOMES AS A PLATFORM FOR MONITORING ORGAN STATUS | Apr 2, 2024 | Pending |
Array
(
[id] => 19246864
[patent_doc_number] => 20240197848
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 IN CHILDREN, APPLICATION OF THE CELL SORTER AND THE METHOD OF MULTIPLYING TREG CELLS TO PRODUCE THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1
[patent_app_type] => utility
[patent_app_number] => 18/588535
[patent_app_country] => US
[patent_app_date] => 2024-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2518
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588535
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/588535 | THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 IN CHILDREN, APPLICATION OF THE CELL SORTER AND THE METHOD OF MULTIPLYING TREG CELLS TO PRODUCE THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 | Feb 26, 2024 | Pending |
Array
(
[id] => 19642941
[patent_doc_number] => 20240417461
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/443894
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51294
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443894
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443894 | NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | Feb 15, 2024 | Abandoned |
Array
(
[id] => 19724050
[patent_doc_number] => 20250026801
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-23
[patent_title] => ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS
[patent_app_type] => utility
[patent_app_number] => 18/423006
[patent_app_country] => US
[patent_app_date] => 2024-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76259
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18423006
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/423006 | ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS | Jan 24, 2024 | Pending |
Array
(
[id] => 19462432
[patent_doc_number] => 20240316101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => REGULATORY T CELL EPITOPES
[patent_app_type] => utility
[patent_app_number] => 18/421039
[patent_app_country] => US
[patent_app_date] => 2024-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18421039
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/421039 | REGULATORY T CELL EPITOPES | Jan 23, 2024 | Pending |
Array
(
[id] => 19462432
[patent_doc_number] => 20240316101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => REGULATORY T CELL EPITOPES
[patent_app_type] => utility
[patent_app_number] => 18/421039
[patent_app_country] => US
[patent_app_date] => 2024-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18421039
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/421039 | REGULATORY T CELL EPITOPES | Jan 23, 2024 | Pending |
Array
(
[id] => 19360848
[patent_doc_number] => 20240262882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => NOVEL RECEPTORS FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION
[patent_app_type] => utility
[patent_app_number] => 18/393538
[patent_app_country] => US
[patent_app_date] => 2023-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393538
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/393538 | NOVEL RECEPTORS FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION | Dec 20, 2023 | Pending |
Array
(
[id] => 19977209
[patent_doc_number] => 12344670
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Anti-ILT4 antibodies and antigen-binding fragments
[patent_app_type] => utility
[patent_app_number] => 18/389914
[patent_app_country] => US
[patent_app_date] => 2023-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 33
[patent_no_of_words] => 29731
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 314
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18389914
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/389914 | Anti-ILT4 antibodies and antigen-binding fragments | Dec 19, 2023 | Issued |
Array
(
[id] => 19528222
[patent_doc_number] => 20240352124
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-24
[patent_title] => Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules that Bind CD3 and CD20, and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/512432
[patent_app_country] => US
[patent_app_date] => 2023-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31760
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512432
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/512432 | Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules that Bind CD3 and CD20, and Uses Thereof | Nov 16, 2023 | Pending |
Array
(
[id] => 19528222
[patent_doc_number] => 20240352124
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-24
[patent_title] => Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules that Bind CD3 and CD20, and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/512432
[patent_app_country] => US
[patent_app_date] => 2023-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31760
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512432
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/512432 | Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules that Bind CD3 and CD20, and Uses Thereof | Nov 16, 2023 | Pending |
Array
(
[id] => 19172478
[patent_doc_number] => 20240158452
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => MATERIALS AND METHODS FOR INDUCING REGULATORY T CELLS
[patent_app_type] => utility
[patent_app_number] => 18/500492
[patent_app_country] => US
[patent_app_date] => 2023-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15745
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500492
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/500492 | MATERIALS AND METHODS FOR INDUCING REGULATORY T CELLS | Nov 1, 2023 | Abandoned |
Array
(
[id] => 18970388
[patent_doc_number] => 20240050480
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => Th1 vaccination priming for active immunotherapy
[patent_app_type] => utility
[patent_app_number] => 18/495532
[patent_app_country] => US
[patent_app_date] => 2023-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18495532
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/495532 | Th1 vaccination priming for active immunotherapy | Oct 25, 2023 | Abandoned |
Array
(
[id] => 19462521
[patent_doc_number] => 20240316190
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING TREGS
[patent_app_type] => utility
[patent_app_number] => 18/495541
[patent_app_country] => US
[patent_app_date] => 2023-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18495541
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/495541 | COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING TREGS | Oct 25, 2023 | Abandoned |
Array
(
[id] => 19172775
[patent_doc_number] => 20240158749
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => GENETICALLY ENGINEERED GAMMA DELTA T CELL
[patent_app_type] => utility
[patent_app_number] => 18/466354
[patent_app_country] => US
[patent_app_date] => 2023-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9036
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 179
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18466354
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/466354 | GENETICALLY ENGINEERED GAMMA DELTA T CELL | Sep 12, 2023 | Pending |